- Q1 2024 Mind Medicine (MindMed) Inc Earnings Call TranscriptMay 08, 2024$9.61 (+0.63%)Earnings
- Q4 2023 Mind Medicine (MindMed) Inc Earnings Call TranscriptFeb 28, 2024$5.35 (-3.78%)Earnings
- Mind Medicine (MindMed) Inc to Host Conference Call TranscriptDec 14, 2023
- Q3 2023 Mind Medicine (MindMed) Inc Earnings Call TranscriptNov 02, 2023$2.7 (+8.43%)Earnings
- Mind Medicine (MindMed) Inc at Cantor Fitzgerald Global Healthcare Conference TranscriptSep 28, 2023
- Q2 2023 Mind Medicine (MindMed) Inc Earnings Call TranscriptAug 03, 2023$4.71 (+2.61%)Earnings
- Mind Medicine (MindMed) Inc at H.C. Wainwright Neuropsychiatry Virtual Conference TranscriptJun 26, 2023
- Mind Medicine (MindMed) Inc at Jefferies Healthcare Conference TranscriptJun 08, 2023
- Mind Medicine (MindMed) Inc at RBC Capital Markets Global Healthcare Conference TranscriptMay 17, 2023
- Q1 2023 Mind Medicine (MindMed) Inc Earnings Call TranscriptMay 04, 2023$3.62 (-1.90%)Earnings
- Mind Medicine (MindMed) Inc at ROTH Conference TranscriptMar 13, 2023
- Mind Medicine (MindMed) Inc at Oppenheimer Healthcare Conference (Virtual) TranscriptMar 13, 2023
- Q4 2022 Mind Medicine (MindMed) Inc Earnings Call TranscriptMar 09, 2023$3.18 (-4.79%)Earnings
- Mind Medicine (MindMed) Inc at Cowen Health Care Conference TranscriptMar 08, 2023
- Mind Medicine (MindMed) Inc at Jefferies London Healthcare Conference TranscriptNov 16, 2022
- Q3 2022 Mind Medicine (MindMed) Inc Earnings Call TranscriptNov 10, 2022$2.6 (+7.88%)Earnings
- Q2 2022 Mind Medicine (MindMed) Inc Earnings Call TranscriptAug 11, 2022$9.75 (-0.21%)Earnings
- Mind Medicine (MindMed) Inc at Canaccord Genuity Growth Conference TranscriptAug 10, 2022
- Mind Medicine (MindMed) Inc at Jefferies Healthcare Conference TranscriptJun 10, 2022
- Q1 2022 Mind Medicine (MindMed) Inc Earnings Call TranscriptMay 16, 2022$12.01 (+2.64%)Earnings
- Q4 2021 Mind Medicine (MindMed) Inc Earnings Call TranscriptMar 28, 2022$17.4 (-1.69%)Earnings
- Q2 2021 Mind Medicine (MindMed) Inc Earnings Call TranscriptAug 16, 2021Earnings
Mind Medicine (MindMed) Inc at ROTH Conference Transcript
And with me now is the CEO of MindMed, Rob Barrow. Welcome, Rob. Nice to have you.
Questions & Answers
So regarding the relatively potent hallucinogens as potential commercial drugs, can you describe the regulatory environment both here and in Europe for a fairly new class of drugs that can take people in different directions?
()-&
Absolutely. Thanks so much for having us here in the conference. So for anyone who is not deeply acquainted with Mind Medicine, we're developing a portfolio of molecules for a variety of brain health disorders, the furthest along of which is a proprietary form of LSD, which we're developing for generalized anxiety disorder, Phase 2b study this year.
We're also developing other models by using these molecules, including a sub-perceptual,
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)